In the CANTOS trial, patients with prior MI and hs-CRP levels of > 2 mg/mL were treated with the IL-1β neutralizing antibody canakinumab once every 3 months and had a median follow-up of 3.7 years, leading to less HHF [69]. Here, IL1B is linked to myocardial infarction.